Social Wall
Efficacy of Nipcalimab To Treat Myasthenia Gravis: Updates From Vivacity-MG3 Trial
Safety and Efficacy of Zilucoplan to Treat Myasthenia Gravis: Results from the RAISE Trial
Positive Results From MINT Study of Uplizna for Myasthenia Gravis
Long-Term Safety of Trofinetide for Rett Syndrome in Younger Children (2-4 years)
Improved Growth in Children Suffering from Fabry Disease Treated With Agalsidase Beta
Treatment Comparisons for Left Ventricular Mass Index in Fabry Disease
Five-Year Study Results in Patients With Fabry Disease
Results From the Phase 3 Vivacity-MG3 Study in Myasthenia Gravis
FDA Approves Treatment for Transthyretin Amyloid Cardiomyopathy
Recent Advances in Fabry Disease Clinical Research
Phase 3 BRIGHT Study in Patients With Fabry Disease
FDA Approves Lumryz for Treatment of Narcolepsy
Recent Guidelines for Myasthenia Gravis
Effects of Inebilizumab to Treat Myasthenia Gravis
Efgartifimod in Seronegative Myasthenia Gravis
Long-Term Safety of Zilucoplan in Patients With Myasthenia Gravis
Positive Results in Vivacity-MG3 Study for Myasthenia Gravis
Social Determinants of Health in Rare Diseases
Traditional vs. Novel Therapies for Myasthenia Gravis
Real-World Experience With C5 Complement Inhibition vs FcRn Antagonism in Myasthenia Gravis
Efficacy of Nipcalimab To Treat Myasthenia Gravis: Updates From Vivacity-MG3 Trial
CheckRare April 21, 2025 11:58 am